Phase I monotherapy dose escalation of RGX-202, a first-inclass oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors

This article has no abstract
Epistemonikos ID: 7e6c28233a782b80d287576cb6d50937438e78e9
First added on: Feb 12, 2025